WuXi PharmaTech (NYSE: WX ) is expected to report Q2 earnings on Aug. 13. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict WuXi PharmaTech (Cayman)'s revenues will expand 24.6% and EPS will improve 24.0%.
The average estimate for revenue is $125.9 million. On the bottom line, the average EPS estimate is $0.31.
Last quarter, WuXi PharmaTech booked revenue of $118.0 million. GAAP reported sales were 26% higher than the prior-year quarter's $93.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.33. GAAP EPS of $0.29 for Q1 were 21% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 35.5%, 160 basis points worse than the prior-year quarter. Operating margin was 17.5%, 370 basis points worse than the prior-year quarter. Net margin was 17.8%, 170 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $486.4 million. The average EPS estimate is $1.26.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 330 members out of 350 rating the stock outperform, and 20 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 68 give WuXi PharmaTech a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech is outperform, with an average price target of $17.68.